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Plasminogen activator inhibitor-type 1 (PAI-1) is the
primary inhibitor of endogenous plasminogen activators that generate plasmin in the vicinity of a thrombus
to initiate thrombolysis, or in the pericellular region of
cells to facilitate migration and/or tissue remodeling. It
has been shown that the physiologically relevant form of
PAI-1 is in a complex with the abundant plasma glycoprotein, vitronectin. The interaction between vitronectin and PAI-1 is important for stabilizing the inhibitor
in a reactive conformation. Although the complex is
clearly significant, information is vague regarding the
composition of the complex and consequences of its formation on the distribution and activity of vitronectin in
vivo. Most studies have assumed a 1:1 interaction between the two proteins, but this has not been demonstrated experimentally and is a matter of some controversy since more than one PAI-1-binding site has been
proposed within the sequence of vitronectin. To address
this issue, competition studies using monoclonal antibodies specific for separate epitopes confirmed that the
two distinct PAI-1-binding sites present on vitronectin
can be occupied simultaneously. Analytical ultracentrifugation was used also for a rigorous analysis of the
composition and sizes of complexes formed from purified vitronectin and PAI-1. The predominant associating species observed was high in molecular weight (Mr ⬃
320,000), demonstrating that self-association of vitronectin occurs upon interaction with PAI-1. Moreover,
the size of this higher order complex indicates that two
molecules of PAI-1 bind per vitronectin molecule. Binding of PAI-1 to vitronectin and association into higher
order complexes is proposed to facilitate interaction
with macromolecules on surfaces.
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lation, in the extracellular matrix of endothelial cells, in platelets, and within various tissues of the human body. Circulating
at micromolar levels, vitronectin participates in the regulation
of humoral responses such as coagulation, fibrinolysis, and the
complement cascade (reviewed in Ref. 1– 4). Other functions of
the protein that are confined to surfaces or tissues include
cell-adhesion and regulation of pericellular proteolysis. Interactions with an assortment of biological molecules are responsible for the multiple functions exhibited by vitronectin. Defining the binding sites for these various biomolecules, along with
determining the molecular mechanism of regulation, constitutes an active area of research on the protein. Work to date
has focused on binding sites for several ligands, including heparin, PAI-1,1 and integrins; a working model representing the
domain structure of vitronectin has been recently reported
from this laboratory (5).
Arguably, one of the most important interactions known for
vitronectin occurs with the serine protease inhibitor, PAI-1.
PAI-1 is the physiological inhibitor of plasminogen activators,
both tPA and uPA, the enzymes responsible for generating
plasmin from its inactive zymogen precursor, plasminogen, and
ultimately leading to clot lysis. In addition to contributing to
the delicate balance required between coagulation and thrombolysis, PAI-1 plays a role in regulating the proteolytic processes responsible for tissue remodeling and metastasis (6).
Although PAI-1 is inherently rather unstable, converting
readily from an active to an inactive, latent form, vitronectin
binds to PAI-1 and maintains the inhibitor in its active conformation for a longer period of time. Indeed, most circulating
PAI-1 is thought to be complexed with vitronectin, so that the
complex serves as a reservoir of the physiologically active form
of PAI-1 (7).
The conversion of active PAI-1 to its latent form is appreciated at the structural level from x-ray crystallographic work by
Goldsmith and colleagues (8). The active-to-latent transition of
PAI-1 involves incorporation of a surface-exposed loop containing the reactive center into the central ␤-sheet of the protein.
Using site-directed mutagenesis (9) and monoclonal antibodies
(10), a vitronectin-binding site on the surface of PAI-1 has been
localized to residues that lie within the central ␤-sheet and
within adjacent secondary structures. An appealing interpre1
The abbreviations used are: PAI-1, plasminogen activator inhibitor
type 1; serpin, serine protease inhibitor; tPA, tissue-type plasminogen
activator; uPA, urokinase-type plasminogen activator; NBD, N,N⬘-dimethyl-N-(acetyl)-N⬘-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine;
S338C, recombinant PAI-1 with cysteine substituted for serine 338 (the
P9 position); NBDP9 PAI-1, S338C mutant form of PAI-1 labeled with
NBD; mAb, monoclonal antibody; BSA, bovine serum albumin; PBS,
phosphate-buffered saline.
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tation of these results is that vitronectin contacts residues on
adjacent structures in the vicinity of the central ␤-sheet of the
protein, thus constraining movement of the strands that is
necessary for incorporation of the reactive loop into the central
␤-sheet in latent PAI-1 (9). The limited freedom of movement of
the ␤-strands to accommodate loop insertion accounts for the
slower rate of conversion of PAI-1 to a latent form when complexed with vitronectin.
On the other hand, the localization of the binding site for
PAI-1 on vitronectin has been more controversial. The PAI-1binding site has been evaluated using proteolysis, synthetic
peptides, and site-directed mutagenesis; however, conclusions
from these studies are contradictory (reviewed in Ref. 11). The
N-terminal 44 amino acids (known as the “somatomedin B”
region) of the protein are proposed by some groups to constitute
the PAI-1-binding site (12–15). Recent evidence that indicates
this region of the protein is responsible for binding PAI-1 comes
from work using isolated recombinant N-terminal fragments
from vitronectin that bind and stabilize PAI-1 (14). Furthermore, site-directed mutagenesis within the recombinant somatomedin B region has identified all 8 cysteines and several
other residues within the 44-amino acid stretch as important
for binding (15).
Other investigators have identified sequences distal to the
N-terminal somatomedin B region to be involved in binding of
the serpin. Notably, some have localized PAI-1 binding to the
positively charged region of the protein from amino acids 345–
379 (16 –20), the site known to be responsible for heparin binding to vitronectin. Proteases that cleave within the heparinbinding region have been shown to diminish PAI-1 binding to
vitronectin, and a recent study demonstrated stabilization of
PAI-1 activity in the presence of a synthetic peptide derived
from the heparin-binding region (21). Also, Seiffert (22) suggests that ligand binding to the C-terminal heparin-binding
region regulates the binding of PAI-1 to the N-terminal somatomedin B region. Seiffert and Smith (23) further argue that the
N-terminal somatomedin B and cell-binding regions are cryptic
in the native structure of vitronectin. Thus, reports in the
literature support PAI-1 binding and stabilization via two distinct regions of vitronectin. Although another proposed site for
PAI-1-binding consists of residues 115–121 (24), there is no
evidence showing specific stabilization of PAI-1 by interactions
with this region of the protein.
A major objective of this work was the direct demonstration
of the size and stoichiometry of PAI-1䡠vitronectin complexes.
These experiments are important for several reasons: (i) more
than one binding site for PAI-1 has been reported on vitronectin; (ii) the binding stoichiometry for the interaction has not
been carefully evaluated previously; (iii) a proposal has been
made that PAI-1 binding induces self-association of vitronectin
(25), and (iv) formation of the complex alters functional properties and stabilities of the two interacting proteins. Accurate
methods for determining molecular weights and stoichiometries are needed to address these issues. In this study, analytical ultracentrifugation was used to directly observe complexes
that form in solution. The sedimentation equilibrium method
provides accurate determinations of molecular weights for mixtures of interacting components. Monoclonal antibodies for different epitopes on vitronectin provided evidence for two PAI1-binding sites. The findings expand on the initial observation
that PAI-1 promotes association of vitronectin by demonstrating a binding stoichiometry for PAI-1䡠vitronectin that is not 1:1,
as well as a discrete associating species that is formed as the
two proteins interact.
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EXPERIMENTAL PROCEDURES

Materials—Vitronectin was isolated from human plasma as described previously (26) using a method adapted from the original purification scheme of Dahlback and Podack (27). Wild type recombinant
PAI-1 was purified from Escherichia coli strains engineered to overexpress the protein essentially as described by Lawrence et al. (28). PAI-1
purified from cells expressing the protein was separated into its active
and latent components using the protocol determined by Kvassman and
Shore (29). Plasma vitronectin has a molecular weight of 72,000, and
recombinant PAI-1 has a molecular weight of 43,000. Generation of the
mutant form of PAI-1 (S338C) containing cysteine at the P9 position
has been previously reported (30), as has the labeling of S338C PAI-1
with the NBD probe (30). NBD (from Molecular Probes) has an extinction coefficient at 470 nm of 23,000 M⫺1 cm⫺1. A monoclonal antibody,
MAI-12, directed against active PAI-1 that neutralizes the reactive
center without interfering with vitronectin binding (31) was obtained
from Biopool, Inc. (Sweden). Two monoclonal antibodies that recognize
vitronectin were used in this work: mAb 8E6 was purchased from Roche
Molecular Biochemicals, and mAb 153 was a kind gift from Dr. David
Loskutoff and Dr. Deitmar Seiffert, Scripps Research Institute, La
Jolla, CA. 125I labeling of MAI-12 IgG was performed using 125I-BoltonHunter reagent (di-iodinated) from ICN Biomedicals. Plastic microtiter
plates (Immunolon II) were a product of Corning. Urokinase (high
molecular weight two-chain uPA, 3000 IU/ml) was purchased from
American Diagnostica, Inc.
Analytical Ultracentrifugation—Equilibrium analytical ultracentrifugation was performed using a Beckman Optima XL-A or Optima XL-I
instrument, essentially as described (26). Tests for equilibrium were
performed by subtraction of successive scans spaced at 4 – 8-h intervals
until no changes in the exponential distribution were observed in three
consecutive scans. Equilibrium was achieved within 24 –36 h. The distribution of a single, homogeneous species within the ultracentrifuge
cell at equilibrium is given by,
cr ⫽ cm exp共兲 ⫹ base

 ⫽ M共1 ⫺ 兲 共r ⫺
2

2

rm2兲/2RT

(Eq. 1)
(Eq. 2)

in which cr and cm are the concentrations of the protein at radial
position, r, and at a reference position (i.e. the meniscus), respectively,
within the cell. M is the protein molecular weight,  is the partial
specific volume, equal to 0.73 ml g⫺1,  is the angular velocity,  is
solvent density, r is the distance in cm from the center of the rotor, rm
is the radial position in cm of the reference from the center of rotation,
R is the gas constant, and T is absolute temperature. The “base” term
is a constant that corrects for non-sedimenting baseline absorbance (or
fringes measured). The partial specific volume was calculated from the
composition of vitronectin and PAI-1, and its use for analysis of equilibrium centrifugation data yields reliable molecular weights for the
isolated monomeric proteins using Equation 1. The calculation of partial specific volume for vitronectin from its amino acid and oligosaccharide composition was previously reported and used in published ultracentrifugation analyses on vitronectin (26). For an associating system,
at chemical and sedimentation equilibrium, in which, for example, A ⫹
B N AB, the sedimentation behavior of each individual macromolecular
species, A, B, and AB, is also given by the exponential distribution
described above (32). The total macromolecule concentration at any
radial position is equal to the sum of all of the individual species, i.e. A
⫹ B ⫹ AB, and the overall distribution of macromolecules is given by
the sum of the individual contributions for each species, A, B, and AB,
as,
cr ⫽ cm,A 䡠 exp共A兲 ⫹ cm,B 䡠 exp共B兲 ⫹ cm,AB 䡠 exp共AB兲 ⫹ base

(Eq. 3)

According to the law of mass action, cAB equals cA*cB/KAB, in which KAB
equals the equilibrium constant for the associating system. Thus Equation 3 shows that sedimentation and chemical equilibria exist at all
radial positions in the ultracentrifuge cell. Equation 3 may be generalized in the form of Equation 4, for species i.
cr ⫽

冘

cm,i 䡠 exp共i兲 ⫹ base

(Eq. 4)

It should be noted that this equation is applicable to any mixture of
sedimenting species. The monomer molecular weights for vitronectin
and PAI-1 determined using Equation 1, as described above, were used
in Equation 4 to calculate the molecular weight of the complex. Data
were analyzed using nonlinear least squares methods, as described by
Brooks et al. (33), using IGOR (Wavemetrics, Lake Oswego, OR) on a
Macintosh Centris 650 or PowerMac computer.
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FIG. 1. Effects of anti-vitronectin mAbs on PAI-1 binding to vitronectin. Panel A, microtiter plate wells were coated overnight with 50
l of vitronectin (1 g/ml). After washing, the wells were blocked with 3% BSA in PBS and then incubated with PAI-1 (2 g/ml) in the presence
of the indicated concentrations of either mAb 153 (open triangles) or mAb 8E6 (closed circles). Bound PAI-1 was detected with 125I-labeled MAI-12.
The amount of PAI-1 bound is expressed on the y axis as a percentage of the PAI-1 bound to vitronectin in the absence of any competing antibodies.
Panel B, microtiter plate wells were coated overnight with 50-l solutions of vitronectin (1 g/ml). After washing, the wells were blocked with 3%
BSA in PBS. Then varied concentrations of PAI-1 were incubated with the bound vitronectin in the presence of fixed concentrations of mAb 153
(5 g/ml; closed squares), mAb 8E6 (5 g/ml; closed triangles), or buffer only (open circles). After washing, the wells were incubated with 160
units/ml urokinase for 30 min at room temperature; remaining urokinase activity was determined by monitoring hydrolysis of chromogenic
substrate for uPA, S-2444 (1 mM concentration), at 405 nm. The concentration of functional PAI-1 bound to vitronectin on the solid-phase was
calculated relative to a titration curve using known concentrations of PAI-1 and uPA in solution. The amount of active PAI-1 is expressed relative
to the maximal amount bound in these experiments at saturating PAI-1 concentrations (⫽0.5 g ml⫺1) in the absence of either competing antibody.
PAI-1䡠Vitronectin Binding Immunoassay—The wells of 96-well Immunolon II microtiter plates were coated overnight, at 4 °C, with
1 g/ml vitronectin in PBS. Unbound vitronectin was washed from the
wells, and nonspecific binding sites were blocked by incubation with 3%
BSA, 0.05% Tween 20 in PBS for 1 h at room temperature. The vitronectin-coated plates were then incubated for 1 h at 37 °C with varying
concentrations of PAI-1 diluted in Tris-buffered saline, pH 7.4, containing 1% BSA. In some experiments, PAI-1 was incubated with the
vitronectin-coated wells in the presence of either mAb 153 or mAb 8E6.
Unbound PAI-1 was then aspirated, and the wells washed three times
with PBS containing 0.1% BSA and 0.05% Tween 20. To detect bound
PAI-1, the plates were incubated for 45 min with 125I-MAI-12 (100,000
cpm/well). The plates were then washed, and the radioactivity remaining in each well determined using a ␥-counter.
PAI-1 Activity Assay—Microtiter plate wells coated with vitronectin
as described above were incubated with increasing concentrations of
PAI-1 in the presence or absence of mAb 153 or mAb 8E6. Unbound
PAI-1 was then aspirated, and the wells washed three times with PBS
containing 0.1% BSA and 0.05% Tween 20. uPA at a final concentration
of 160 IU/ml (100 l) was then added to each well and incubated for 30
min at 23 °C. Chromogenic substrate S-2444 was added to a final
concentration of 1 mM. Residual uPA activity was determined by quantifying the change in absorbance at 405 nm. Rates of substrate hydrolysis were calculated for each of the various experimental conditions and
expressed as a percentage of the maximum rate of uPA substrate
hydrolysis in the absence of PAI-1.
Solid Phase mAb 8E6/153 Binding Assays—The availability of
epitopes on vitronectin for mAbs 153 and 8E6 was determined in a solid
phase binding assay. Briefly, the microtiter plate wells were coated
overnight at 4 °C with either mAb 153 or 8E6 (both at a concentration
of 7.5 g/ml). Nonspecific binding sites were then blocked with 3% BSA,
0.05% Tween 20 in PBS for 1–1.5 h, and the mAb-coated wells were
incubated with a saturating concentration (2 g/ml solution) of
vitronectin in PBS containing 0.1% BSA and 0.1% Tween 80. The wells
were then rinsed as described above. Subsequently, the bound vitronectin was incubated with varying concentrations of the antibody that was
not used in the capture phase, i.e. mAb 8E6 or 153, respectively. The
wells were then washed thoroughly and incubated with PAI-1 (2 g/ml
concentration in PBS) for 1 h at 37 °C. After washing, bound PAI-1 was
detected using 125I-labeled MAI-12 IgG (100,000 cpm/well) as described
above.
RESULTS

Monoclonal Antibodies Specific for Different Epitopes on
Vitronectin Were Used to Evaluate the Models of One versus
Two PAI-1-binding Sites on the Protein—Monoclonal antibod-

ies against specific sites on vitronectin have been particularly
useful over the years in localizing functions on the protein.
However, in the case of PAI-1 binding to vitronectin, the results
using different antibodies have been ambiguous. The monoclonal antibodies most frequently used in structure-function
work relating to PAI-1 binding to vitronectin are mAb 8E6 (34,
35), specific for an epitope within the large central CNBr fragment from vitronectin (36), and mAb 153, which recognizes the
PAI-1-binding epitope within the extreme N-terminal somatomedin B region (14). Both antibodies have been shown to block
PAI-1 binding to vitronectin; in the case of mAb 8E6, the
interference with PAI-1 binding was proposed to result from
masking of the heparin-binding site (16). To further evaluate
one versus two potential binding sites for PAI-1 on vitronectin,
these antibodies were directly compared in this study for their
ability to compete with PAI-1 for binding to vitronectin.
Fig. 1A presents data from an experiment in which vitronectin is coated on microtiter plates, followed by incubation with a
fixed concentration of PAI-1 in solution with varying concentrations of either mAb 8E6 or 153. The results show that both
of the monoclonal antibodies tested interfere with PAI-1 binding to vitronectin. However, it is notable that neither of the
antibodies fully blocks binding. In fact, each reduces binding of
PAI-1 to vitronectin only by about half. This is the first time
that effects of these antibodies on PAI-1 binding have been
directly compared in the same assay, and the results are compelling in their support of two distinct PAI-1-binding sites on
vitronectin.
Fig. 1B summarizes results from a similar experiment in
which vitronectin is immobilized on the solid-phase, followed
by incubation with varied concentrations of PAI-1 in the presence of a fixed concentration of one of the two mAbs. Bound
PAI-1 is detected in this experiment using a functional assay
based on inactivation of uPA by the serpin. Both monoclonal
antibodies interfere with the binding of PAI-1, with a decreased
amount of active PAI-1 bound. Moreover, neither of the mAbs
inhibited 100% of the PAI-1 binding. The addition of both
antibodies in these experiments inhibited PAI-1 binding to a
greater extent than observed with either antibody alone, with
inhibition to ⬎90%.

Stoichiometry of Vitronectin䡠PAI-1 Complexes

FIG. 2. Accessibility of PAI-1-binding sites on vitronectin
bound to the solid-phase by a specific reaction with monoclonal
antibodies. Microtiter wells coated with either mAb 153 (open triangles) or mAb 8E6 (closed circles) were incubated with vitronectin at a
saturating concentration (2 g/ml in PBS). Subsequently, the bound
vitronectin was incubated with varying concentrations of the antibody
that was not used in the capture phase, i.e. mAb 8E6 or mAb 153,
respectively. The wells were then washed thoroughly and incubated
with PAI-1 (2 g/ml concentration in PBS), and bound PAI-1 was
detected using 125I-labeled MAI-12. Bound radioactivity is expressed as
a percentage of the amount of PAI-1 bound to vitronectin in the absence
of the second competing anti-vitronectin mAb.

In a different approach to evaluate whether the two monoclonal antibodies compete for PAI-1-binding sites on vitronectin, separate sets of microtiter plates were coated with either of
the two antibodies. Subsequently, vitronectin was specifically
bound via the corresponding epitope recognized by the solidphase antibody. Immobilizing vitronectin in an immunospecific
fashion such as this avoids conformational perturbations that
are known to occur when vitronectin is adsorbed to plastic
surfaces (37–39). This was reasoned to be a better approach for
testing effects of blocking both epitopes on vitronectin because
all vitronectin bound to the solid-phase is, by design, blocked at
one epitope. Thus, the bound vitronectin retains its native
conformation for binding to PAI-1 or to the second antibody.
Homogeneity of both antibodies binding to solid-phase
vitronectin would not be expected due to conformational
changes that are known to affect immunoreactivity. PAI-1 was
then incubated with the bound vitronectin in the presence of
varying concentrations of the other mAb that was not used in
the capture phase. As the results in Fig. 2 illustrate, PAI-1
binding to vitronectin is severely impaired (⬎90%) in the presence of both antibodies. That is, PAI-1 can be bound to vitronectin if only one of the epitopes is occupied by antibody, but its
binding is negligible when both epitopes are blocked specifically with the corresponding monoclonal antibodies. Interestingly, the percentage of PAI-1 bound is nearly equivalent in
both scenarios, regardless of which antibody is used in the
capture or competing phases in the study.
Sedimentation Equilibrium Measurements Were Used to Observe the Sizes of Complexes Formed between Vitronectin and
PAI-1—In light of the observation that PAI-1 may bind at
either or both of two potential binding sites on vitronectin, a set
of experiments was designed using various ratios of vitronectin
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to PAI-1 to evaluate the molar equivalence of complexes.
Table I summarizes the efforts to characterize these two interacting proteins using ultracentrifugation, including experiments that were conducted with altered ratios of the two proteins, different protein preparations and variations in rotor
speeds. Representative results from a sedimentation equilibrium experiment with 2 ⫻ 10⫺6 M active PAI-1 and 2 ⫻ 10⫺6 M
vitronectin are shown in Fig. 3. Experimental data points representing the radial distribution of total absorbance at 280 nm
are shown in the solid squares. The smooth curve through the
data represents a non-linear fit composed of the sum of the
radial distributions for the contributing species. The best fit to
the data required a model with more than one interacting
component, with a distribution of the two species along the
radial length of the cell. Mathematical deconvolution of the
data into the contributing species is shown by the two exponential traces below the experimental data in Fig. 3. This
analysis of the data is rigorous and treats complex formation as
a function of the concentrations of the interacting proteins
which varies along the length of the cell at equilibrium as a
function of rotor speed, temperature, and total protein
concentration.
At equilibrium, only two protein species are detected; one
has a molecular weight of 72,000, corresponding to the molecular weight of vitronectin, and a second species is observed
with a molecular weight of 317,000. Negligible free PAI-1 (molecular weight of 43,000) is detected. Similarly there is no
evidence for a protein species with intermediate molecular
weight, i.e. between 72,000 and 320,000. The high molecular
weight species clearly represents a complex formed by vitronectin and PAI-1. The analysis for the size of the complex indicates
a species with a calculated mean molecular weight of 324,000 ⫾
14,000 that was fairly consistent among a number of analyses
(Table I) with mixtures of the interacting proteins tested under a
variety of conditions. The analysis of the data is not indicative of
a broad distribution of oligomeric species in these experiments.
The observation of only two species at equilibrium indicates
that an equimolar mixture of proteins does not give a stoichiometric complex or a depletion of free reactants under these
conditions. Mixing equal, approximate micromolar concentrations of the two proteins would have been expected to yield a
species of 115,000 molecular weight, with little free vitronectin
or PAI-1, if a tight complex with 1:1 stoichiometry were formed.
First, the complex formed is not a simple 1:1 complex of
vitronectin and PAI-1, as it is larger than the expected 115,000;
and second, there is apparently some free vitronectin “leftover”
that is not found as part of the high molecular weight complex,
although there are negligible amounts of free PAI-1, arguing
against a 1:1 stoichiometry for the reactants. The findings are
more consistent with the binding of two PAI-1 molecules to
each molecule of vitronectin, with an overall stoichiometry of 4
PAI-1䡠2 vitronectin yielding a complex of 316,000 molecular
weight. (The molecular weight for the 2:1 complex equals
158,000.) The analysis of equilibrium sedimentation data summarized in Table I, along with the immunochemical data, argue
strongly for this 4:2 complex. Note that a 3:3 complex of PAI1䡠vitronectin would have a predicted molecular weight of
345,000 that is near the upper limit of these measurements and
may be within experimental error. However, the composition of
a 3:3 complex is less compatible with the immunochemical data
arguing for binding at two sites on vitronectin. Moreover, a
stoichiometric n:n complex (with n equal to any number of
vitronectin and PAI-1 monomers) is not compatible with the
ultracentrifugation results that show a substantial amount of
free vitronectin when equimolar concentrations of the two proteins are mixed.
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TABLE I
Equilibrium ultracentrifugation experiments on vitronectin and PAI-1 mixtures

Experiment No.
instrument/wavelength

[Vitronectin] ⫻ 10⫺6

1
XLI/Interference

2

M

[PAI-1]a ⫻ 10⫺6

M

Rotor Speed

Mr of species from fitb

Chi squared

rpm

2a
XLA/280 nm
2b
XLA/501 nm
3a
XLA/280 nm
3b
XLA/280 nm
4a
XLA/280 nm

7.9

2

15,000

4.1 (NBD-PAI-1)

16,000
16,000

2

2

16,000

2

2

16,000

2

2

(NBD-PAI-1)

12,000

4b
XLA/280 nm

16,000

4c
XLA/280 nm

10,000

5a
XLA/280 nm
5b
XLA/280 nm
5c
XLA/280 nm

0.9

2.4 (NBD-PAI-1)

12,000
16,000
10,000

352,000 ⫾ 5,000
72,000
43,000
315,000 ⫾ 4,000
72,000
43,000
308,000 ⫾ 3,000c
43,000
317,000 ⫾ 3,000d
72,000
328,000 ⫾ 2,000
72,000
43,000
322,000 ⫾ 3,000
72,000
43,000
317,000 ⫾ 5,000
72,000
43,000
326,000 ⫾ 9,000
72,000
43,000
323,000 ⫾ 2,000e
43,000
335,000 ⫾ 2,000e
43,000
316,000 ⫾ 9,000e
43,000

0.039
0.013
0.0015
0.03
0.024
0.012
0.011
0.009
0.0014
0.0015
0.0013

a
Unless otherwise specified, PAI-1 used in the experiments was wild type recombinant protein that is unlabeled. NBD-labeled PAI-1 is used in
experiments as indicated in parentheses.
b
Molecular weight of the complex ⫾ S.E. is given from the fit to multiple species according to Equation 4. The molecular weight of free vitronectin
or free PAI-1 was fixed as 72,000 or 43,000 as indicated.
c
Note that there is no free vitronectin in the fit because the label at 501 nm exclusively detects the NBD-labeled PAI-1.
d
The solution denoted as Experiment 3a is the first fit to this data, including only free vitronectin and complex with no free PAI-1. This is the
data deconvolution shown in Fig. 3. Experiment 3b is the data fit to all three components, yielding a better value for Chi squared.
e
Free vitronectin is not included in these fits because of the excess of PAI-1 over vitronectin in the centrifuge cell.

As a test for association between vitronectin and the latent
form of PAI-1, an equimolar mixture of the two proteins was
analyzed by sedimentation equilibrium. As shown in Fig. 4, the
exponential distribution of protein in the cell corresponded to
the sum of both of the free proteins, with no evidence for
association to give a complex. This result supports previous
work that used other methods to show that latent PAI-1, as
well as any form of PAI-1 with a rearranged central ␤-sheet
containing the fifth ␤-strand, bound only weakly to vitronectin
(40). The analytical ultracentrifugation experiment used here
extends these previous findings by showing that micromolar
concentrations of vitronectin and latent PAI-1 do not associate.
A Unique Label on PAI-1 Indicates That the Serpin Is Present
in the High Molecular Weight Complex—A powerful approach
that was used in these experiments to distinguish the two
reactant proteins was to specifically incorporate a chromophore
into PAI-1 (30). A mutant form of PAI-1 with a cysteine substituted at the P9 position was labeled with NBD, providing a
probe specific to PAI-1 that is monitored in the visible wavelength region. This form of PAI-1 is an active inhibitor of
tissue-type plasminogen activator and urokinase (30), and it
has been used in this laboratory in fluorescence studies to
characterize conformational changes that accompany the interaction of PAI-1 and vitronectin (41). The labeled mutant allowed for PAI-1 and vitronectin to be distinguished spectrally
in the ultracentrifuge. (A number of experiments are summarized in Table I.) As shown in Fig. 5A, the PAI-1-containing
species can be exclusively monitored around 500 nm, near the
absorption maximum for the NBD probe on the inhibitor. Once
again, the distribution of absorbing species at equilibrium cannot be adequately fit to only a single species. Measurements at

this wavelength clearly show the presence of the high molecular weight (approximately 320,000) complex, and there is also
evidence for some free labeled PAI-1 (due to a small amount of
latent protein in the PAI-1 preparation). This experiment conclusively demonstrates the presence of PAI-1 as an integral
component of the complex, as opposed to the complex being
formed solely of self-associated vitronectin species.
Fig. 5B shows the results of the same sample mixture analyzed at 280 nm, which detects both PAI-1 and vitronectin,
rather than at 501 nm for PAI-1 components only. The fits
shown use the concentration of free PAI-1 and PAI-1-containing complex determined using the 501 nm data in Fig. 5A. The
protein species observed are quite consistent in size and relative concentration with the results summarized in Table I. Note
that the amount of free (latent) PAI-1 is the same in both
panels, although it appears more prominently in data collected
at 501 nm because vitronectin does not contribute to absorbance at this wavelength. The fact that the NBD-labeled PAI-1
forms the same ⬃320,000 molecular weight complex with
vitronectin as does wild-type PAI-1 (Table I) in the ultracentrifuge studies confirms the observation that the label on PAI-1
does not perturb its function or interaction with vitronectin (30,
41). The ultracentrifugation data indicate that the composition
of the complex formed from an equimolar mixture of PAI-1 and
vitronectin is not equimolar. Free vitronectin in addition to the
complex is observed in these mixtures of the two proteins, and
the data support a model for a complex composed of two molecules of vitronectin and four molecules of PAI-1 with a predicted molecular weight of 316,000. Obviously, it is not possible
from these data alone to distinguish between a model in which
two PAI-1 molecules are bound to a single site versus a model
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FIG. 3. Representative sedimentation equilibrium measurements on an equimolar mixture of vitronectin and PAI-1.
Vitronectin (2 ⫻ 10⫺6 M) and PAI-1 (2 ⫻ 10⫺6 M) were mixed in a buffer
of 0.1 M HEPES, 0.1 M NaCl, pH 7.4. 130 l of this sample was loaded
in the ultracentrifuge cell, and the sample was centrifuged at 16,000
rpm at 4 °C for a period of 48 h until equilibrium was reached. Absorbance at 280 nm versus radial distance at equilibrium is shown by the
solid squares in the large panel. The non-linear least squares fit to the
data assuming 2 interacting molecular species is shown by the solid line
through the data. The residuals for the fit are shown in the small panel
at top. In order to determine the relative contribution of the two species
to the total absorbance at 280 nm at all distances in the cell, mathematical deconvolution into two components was performed using the
equations given under “Experimental Procedures.” This deconvolution
of the curve into its constituents is shown by the two exponential traces
below the experimental data, marked Free VN (vitronectin) (Mr ⬃ 72,000)
and 317,000. The horizontal line corresponding to a value near zero
represents non-sedimenting baseline absorbance (base in Equation 4).

with two distinct binding sites for PAI-1 on vitronectin.
A rigorous analysis of the composition of the complex comes
from calculations on the sedimentation equilibrium data to
determine actual concentrations of labeled PAI-1 and the high
molecular complex as a function of radial distribution in the
experiment. The data at 501 nm together with the data at 280
nm which were obtained from the same experiment, as shown
in Fig. 6, can be used to directly assess the stoichiometry of
labeled protein (NBD-PAI-1) within the high molecular weight
complex. The absorbance due to the complex alone at 501 and
280 nm were obtained by subtracting the spectral contributions
of free vitronectin and free PAI-1 (known values from the
non-linear fits). This allows for calculation of absorbance at 501
and 280 nm that exclusively correspond to the proteins within
the complex. From the extinction coefficients for NBD at
501 nm and for vitronectin and PAI-1 at 280 nm we determined
the number of NBD-labeled PAI-1 molecules within the complex. As shown in Fig. 6, this ratio is not a function of radial
position indicating that the number of NBD-PAI molecules in
the complex is constant across the cell. The average stoichiometry of NBD-PAI-1 within the complex is approximately 3.5 ⫾
0.5, providing substantial support for the proposed composition
of the complex.
DISCUSSION

The fundamental objective of this work was to determine the
size and stoichiometry of the PAI-1䡠vitronectin complex. The
technique of analytical ultracentrifugation was selected because it provides a rigorous approach to the measurement of
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FIG. 4. Sedimentation equilibrium experiment using an
equimolar mixture of vitronectin and latent PAI-1. Vitronectin
(2 ⫻ 10⫺6 M) and latent PAI-1 (2 ⫻ 10⫺6 M) were mixed in a buffer of 0.1
M HEPES, 0.1 M NaCl, pH 7.4. 130 l of this sample was loaded in the
ultracentrifuge cell, and the sample was centrifuged at 16,000 rpm at
4 °C for a period of 48 h until equilibrium was reached, as described in
the legend to Fig. 1. Absorbance at 280 nm measured over the radial
distance in the cell is shown by the solid squares in the large panel. The
non-linear least squares fit to the data assuming 2 molecular species is
shown by the solid line through the data. The residuals for the fit are
shown in the small panel at top. Deconvolution of the curve into its
constituents is shown by the two exponential traces below the experimental data, marked Latent PAI-1 (Mr ⬃ 43,000) and Free Vitronectin
(Mr ⬃ 72,000). No high molecular weight species were detected in this
experiment. Details of the analyses are given under “Experimental
Procedures.”

protein molecular weights in solution under equilibrium conditions. Prior to this study, the binding data for PAI-1 and
vitronectin had been interpreted assuming a single PAI-1-binding site with a unique affinity. Results from enzyme-linked
immunosorbent-type assays that have primarily been used in
the past are difficult to reconcile because variable binding
affinities are observed, depending on which reactant is immobilized on the plastic surface (42). It is difficult to estimate
stoichiometries of binding from these types of experiments, and
attempts to quantify binding stoichiometries have varied from
a ratio of 1:1 (PAI-1:vitronectin) with immobilized PAI-1 to a
ratio of 1:3 (PAI-1:vitronectin) using immobilized vitronectin
(42). In this report, a combination of immunoassays using two
monoclonal antibodies specific for different epitopes on
vitronectin, and the sensitive ultracentrifugation method to
evaluate molecular weights of associating systems, has clarified stoichiometry issues and provided a new picture of the
PAI-1䡠vitronectin complex.
A Higher Order Complex Is Formed When PAI-1䡠Vitronectin
Complexes Associate—On first inspection, the sedimentation
equilibrium data clearly indicated that a complex other than a
simple 1:1 product formed when vitronectin and PAI-1 interact.
The molecular weight for the complex was consistently found to
equal about 320,000, and the species at equilibrium using
equimolar mixtures of vitronectin and PAI-1 clearly included
lower molecular weight material (free vitronectin or free latent
PAI-1) in addition to the large complex. The ultracentrifuge
data also show that at equilibrium there are no detectable
intervening molecular weight species that would correspond to
potential stable intermediates from the assembly process.
Thus, in the time required to achieve sedimentation equilib-
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FIG. 5. Sedimentation equilibrium measurements on a mixture of vitronectin and NBDP9 PAI-1. Vitronectin (7.9 ⫻ 10⫺6 M) and
NBDP9 PAI-1 (4.1 ⫻ 10⫺6 M) were mixed in a buffer of 0.1 M HEPES, 0.1 M NaCl, pH 7.4. 130 l of this sample was loaded in the ultracentrifuge
cell, and the sample was centrifuged at 16,000 rpm at 4 °C for a period of 48 h until equilibrium was reached. Panel A shows data acquired at 501
nm, the extinction wavelength for the NBD chromophore. Absorbance at 501 nm measured over the length of the cell at equilibrium is shown by
the solid squares. Panel B shows absorbance at 280 nm measured over the length of the cell for the same sample at equilibrium. The non-linear
least squares fit to the data assuming 2 (Panel A) or 3 species (Panel B) is shown by the solid line through the data. The residuals for the fit are
shown in the small insets at top of each panel. In order to determine the relative contribution of the two species to the total absorbance at 501 nm
in panel A at all distances in the cell, mathematical deconvolution into two components was performed using the equations given under
“Experimental Procedures.” The exponentials from the fit to the data in Panel A were fixed, and the deconvolution for the data collected at 280 nm
in Panel B was simplified so that the only unknown was the fit to free vitronectin. The deconvolution of the curves in both panels into their
constituents is shown by the exponential traces below the experimental data, marked Free PAI-1 (Mr ⬃ 43,000), Free Vitronectin (Mr ⬃ 72,000),
or 324,000 (the molecular weight determined for the PAI-1䡠vitronectin complex in many experiments, see Table I and text). At 501 nm, the amount
of free PAI-1 is exaggerated relative to the total molecular species in the cell because of the absorbance scale relative to Panel B; note that the
concentration of free PAI-1 determined in this experiment is the same used in the fit to total protein absorbance shown in Panel B. The horizontal
lines corresponding to values near zero in both panels represent non-sedimenting baseline absorbance (base in Equation 4).

rium, complex formation appears to go to completion.2
A great deal of controversy surrounds the issue of PAI-1binding sites on vitronectin, with sites localized to two distinct
regions of vitronectin. The immunochemical studies performed
here provide insight into the fundamental reason for the debate, namely that both of the regions appear to be functional
PAI-1-binding sites. The mole ratio of 4:2 PAI-1:vitronectin
suggested from the ultracentrifugation experiments was supported by the explicit evaluation of two anti-vitronectin monoclonal antibodies that had given apparently contradictory results in the past regarding PAI-1 binding to vitronectin. The
problem had been that independent research groups had used
these antibodies to consider only one PAI-1-binding site on
vitronectin, residing in the vicinity of one or the other antibody
epitope. This study demonstrates that PAI-1 binding to
vitronectin occurs simultaneously with either of the antibodies,
and PAI-1 binding is fully blocked only if the two binding sites
on vitronectin are saturated with both monoclonal antibodies.
Thus, the data from this study are consistent with binding of
PAI-1 at both sites.
A Different Scheme for Association of PAI-1 and Vitronectin
Complex Must Be Considered—An important result from this
study is the demonstration of a higher-order complex that
contains molecules of both vitronectin and PAI-1. Although the
idea that PAI-1 binding produces multimeric forms of vitronectin has been suggested previously (25), the possibility that the
complex between vitronectin and PAI-1 is not a binary 1:1
species has not been considered or addressed experimentally.
This is despite the observation that circulating PAI-1 is quantitatively bound to vitronectin, and that early size-exclusion
2
Preliminary sedimentation velocity experiments initiated within
minutes of mixing the two proteins suggest the presence of intermediate species. Additional experiments will be required to determine the
composition of these intermediates.

FIG. 6. Evaluation of the amount of PAI-1 in the complex from
absorbance values in the sedimentation equilibrium approach.
The primary data at 280 nm (solid circles) and 501 nm (solid squares)
shown in Fig. 5, Panels A and B, respectively, has been corrected for the
contributions of free vitronectin and/or PAI-1 to the total absorbance.
This correction was made by a simple subtraction of the exponential
distribution of each of the free component species (determined from the
non-linear best fit to the data as calculated in Fig. 5) from the measured
absorbance data. After this correction was made, the ratio of the absorbance data at 501 nm to that at 280 nm was calculated in order to
determine the number of PAI-1 molecules in the high molecular weight
complex (shown in the solid triangles). The amount of PAI-1 in the
complex was calculated using extinction coefficients for the NBD label
at 501 nm of 23,000 M⫺1 cm⫺1 and for the 320,000 molecular weight
complex of 330,000 M⫺1 cm⫺1. The extinction coefficient for the complex
was calculated from the known extinction coefficients at 280 nm for the
component proteins (72,000 M⫺1 cm⫺1 and 43,000 M⫺1 cm⫺1 for PAI-1)
and a contribution of 2,500 M⫺1 cm⫺1 from absorbance of the NBD label
on PAI-1 at 280 nm.

chromatography on the plasma proteins produced a complex
with a molecular weight larger than the 1:1 form (7). The
multifaceted approach to address the questions of reaction
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FIG. 7. A model for the association
of PAI-1 and vitronectin into large
complexes with a stoichiometry of 4:2
(PAI-1䡠vitronectin). Putative intermediates in the assembly process that are
not populated at equilibrium are shown in
brackets. The model assumes binding of
PAI-1 at two sites on vitronectin. Either
the 1:1 or the 2:1 (PAI-1䡠vitronectin) intermediate associates with a second complex via self-association of the vitronectin
components. Following dissociation of the
complex and accumulation of latent PAI-1
at long times, the model proposes that
vitronectin remains self-associated. It is
postulated that even higher order oligomers form from the 4:2 complex or from
associated vitronectin following conversion of PAI-1 to the latent form.

stoichiometry and size of complexes formed by vitronectin and
PAI-1 provides a foundation for proposing a model for the
composition of the associated complex.
A model for the PAI-1䡠vitronectin complex that assumes
binding of PAI-1 at two putative sites on vitronectin is shown in
Fig. 7. In the model, PAI-1 binding leads to association of
vitronectin. The self-association of vitronectin may be favored
upon binding of one PAI-1 molecule, or the binding of PAI-1 to
both sites may be required before the higher order complex is
formed. PAI-1 is stabilized in the complex, although PAI-1 that
is not associated rearranges to the latent form at long times.
Latent PAI-1 and vitronectin do not interact, so the latent form
of the inhibitor accumulates. The low temperature used for
these experiments should be noted, as it allowed the observation of the 4:2 complex, with little conversion of PAI-1 to a
latent form that would not associate, and with little propensity
of the complex to form higher order aggregates that may be
favored at higher temperature. The self-associated forms of
vitronectin remain intact after conversion of all PAI-1 to the
latent form, producing a stable altered form of vitronectin that
is multivalent, as previously proposed (25). Under some conditions, even higher order oligomers may form from the 4:2 complex or from the associated vitronectin that remains after
PAI-1 is released. Note that aged samples exhibit species of
even higher molecular weight that may correspond to higher
order aggregates that form after dissociation of the complex
and conversion of PAI-1 to a latent form.3 The higher order
complex observed in the ultracentrifugation experiments supports the hypothesis that PAI-1 binding promotes self-association of vitronectin.
At the micromolar protein concentrations used in this work,
PAI-1 binds to both sites and gives large complexes. The PAI-1
concentration used experimentally is clearly higher than that
in the circulation, which is approximately 0.5 nM. However, the
concentration of PAI-1 in either venous or arterial thrombi is
several orders of magnitude greater than in the circulation
(43– 47). Recent immunohistochemical studies suggest that,
like PAI-1, vitronectin is concentrated along fibrin fibrils
within thrombi in situ (45). Also, vitronectin and PAI-1 are
stored in relatively high concentrations within platelet ␣-granules, and the majority of vitronectin released upon platelet

activation is high in molecular weight and at least partially
associated with PAI-1 (48). Thus, it appears that the complexes
observed in the ultracentrifugation experiments can readily
form in the vicinity of a blood clot. In fact, recent studies by
Podor and colleagues (49) indicate that vitronectin binds directly to fibrin clots,4 and the fibrin-associated vitronectin mediates the high-affinity binding of PAI-1 to fibrin.
The model in Fig. 7 proposes a physiological means to promote association of vitronectin into higher order species. Similar to the advantage offered by multiple heparin-binding sites
on vitronectin, the self-association of vitronectin may aid in
binding to other ligands, especially cell surface receptors.
Other work has shown that multimeric forms of vitronectin are
preferentially endocytosed via integrins in fibroblasts (50), and
by non-integrin-mediated mechanisms in megakaryocytic cells
which target the internalized vitronectin to ␣-granule structures containing PAI-1 (51). In addition, only vitronectin multimers are functional in binding to the uPA receptor (52, 53).
PAI-1 may be the physiological stimulus for association of
vitronectin to achieve the “clustering” of receptor-binding sites
required for biological activity.

3
K. H. Minor, M. N. Blackburn, and C. B. Peterson, unpublished
observations.

4
T. J. Podor, J. I. Weitz, and C. B. Peterson, submitted for
publication.
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